Related Experiment Video

Updated: Sep 5, 2025

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis
09:55

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis

Published on: October 25, 2024

1.1K

Necroptosis in atherosclerosis

Xiaofan Zhang1, Zhong Ren1, Wenxin Xu1

  • 1Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical School, University of South China, Hengyang 421001, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|July 9, 2022
PubMed

Insights

Necroptosis, a programmed cell death, contributes to atherosclerosis by promoting inflammation in vascular cells and macrophages within plaques. Understanding this process is key to developing new treatments for this leading cause of death.

Area of Science:

  • Cardiovascular Biology
  • Cellular Pathology
  • Inflammatory Diseases

Background:

  • Atherosclerosis is a major global cause of mortality, characterized by chronic inflammation.
  • Key cellular players in atherosclerotic plaque development include vascular endothelial cells (VECs), vascular smooth muscle cells (VSMCs), and macrophages.
  • Necroptosis, a form of programmed necrosis, is observed in advanced atherosclerotic lesions.

Purpose of the Study:

  • To review the pathophysiological role of necroptosis in atherosclerosis.
  • To explore the involvement of necroptosis in VECs, VSMCs, and macrophages within atherosclerotic plaques.
  • To connect necroptosis mechanisms to the progression of atherosclerosis.

Main Methods:

  • Literature review focusing on necroptosis and atherosclerosis.
  • Analysis of studies investigating necroptosis in VECs, VSMCs, and macrophages.
  • Synthesis of current understanding of necroptosis's impact on plaque development and inflammation.

Main Results:

  • Necroptosis occurs in advanced atherosclerotic plaques.
  • This programmed cell death influences the function of VECs, VSMCs, and macrophages.
  • Necroptosis can promote a pro-inflammatory state, potentially accelerating atherosclerosis.

Conclusions:

  • Necroptosis plays a significant pathophysiological role in atherosclerosis.
  • Targeting necroptosis in VECs, VSMCs, and macrophages may offer therapeutic strategies.
  • Further research is warranted to fully elucidate necroptosis's contribution to atherosclerosis.

Keywords:
AtherosclerosisMacrophagesNecroptosisVascular endothelial cellsVascular smooth muscle cells

More Related Videos

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

28.8K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.1K

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
73
Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.8K
Inflammation01:38

Inflammation

Overview
54.9K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
32
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
36